Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06416800 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT06416800 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 71 participants.
The verdict
NCT06416800, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants.
Interventions
- DRUG Metformin
- DRUG Probenecid
- DRUG Povorcitinib
- DRUG Rosuvastatin
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2024-06-19 |
| Est. Completion | 2025-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06416800
The ClinicalTrials.gov registry entry for NCT06416800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT06416800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06416800 about?
NCT06416800 is a clinical study titled "A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants". The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants.
What is the current status of trial NCT06416800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2024-06-19. Estimated completion is 2025-01-15.
What interventions are being tested in trial NCT06416800?
The interventions under investigation include: Metformin (DRUG), Probenecid (DRUG), Povorcitinib (DRUG), Rosuvastatin (DRUG), Digoxin (DRUG).
Who is sponsoring clinical trial NCT06416800?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.